PD-1+ selected tumor infiltrating lymphocytes

PD-1+ selected tumor infiltrating lymphocytes (TIL) is an autologous cell therapy being developed for the treatment of metastatic melanoma. The therapy involves harvesting T cells that have naturally infiltrated a patient's tumor, followed by a specific selection process to isolate the subset of lymphocytes expressing the Programmed Cell Death 1 (PD-1) protein. PD-1 is frequently used as a biomarker for tumor-reactive T cells, as these cells often express PD-1 due to chronic antigen stimulation within the tumor microenvironment. These selected cells are expanded ex vivo in a laboratory setting to create a potent cell product which is then re-infused into the patient, typically following lymphodepleting chemotherapy and in combination with interleukin-2 (IL-2) to support T-cell survival and expansion. This specific selection strategy aims to enhance the proportion of neoantigen-specific T cells within the final product compared to conventional unselected TIL therapies.

Other names

PD-1+ selected TILPD-1 selected tumor infiltrating lymphocytesPD1 selected tumor infiltrating lymphocytesPD 1 selected tumor infiltrating lymphocytesPD-1+ selected TILs